Evaluation of the Analytical Performance of ALLEGRO™ Instrument
Allegro Evaluation Study for FDA Submission
Sponsor: Nova Biomedical
Listed as NCT04096313, this observational or N/A phase trial focuses on Diabetes Mellitus and Kidney Diseases and remains completed. Sponsored by Nova Biomedical, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2022 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Dec 2021 — Jan 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Not Yet Recruiting
▶ Show 4 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting
-
Feb 2020 — Oct 2020 [monthly]
Not Yet Recruiting
-
Dec 2019 — Feb 2020 [monthly]
Not Yet Recruiting
-
Oct 2019 — Dec 2019 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nova Biomedical
For direct contact, visit the study record on ClinicalTrials.gov .